M
M2i Life Sciences
Design, formulation and production of complex molecules
About M2i Life Sciences
M2i Life Sciences is a forward-thinking company that operates in the agroecological sector, focusing on biocontrol products. The company's main objective is to reconcile economic development with environmental concerns and respectful governance. They have been recognized for their ability to balance these aspects, receiving accolades from the Henri Savall Foundation and ISEOR.
Read full description
Their business model revolves around the development and sale of biocontrol products, which are natural alternatives to chemical pesticides. These products are used in agriculture to control pests and diseases, making them attractive to clients in the farming industry who are looking to reduce their environmental impact.
M2i Life Sciences has been successful in expanding its portfolio of approved products, having obtained several approvals for its biocontrol products. These approvals include 3 Marketing Authorization Applications (AMM) for finished products, 2 for active pheromone ingredients, and several AMM extensions in Europe. In simple terms, these approvals mean that M2i's products have been officially recognized as safe and effective, allowing them to be marketed and sold to customers.
The company's revenue is generated through the sale of these biocontrol products. As more farmers and agricultural businesses seek to transition to more environmentally friendly practices, the demand for M2i's products is likely to increase, potentially leading to higher revenues for the company.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Saint-Cloud, France
- Employees
- 133
- Open positions
- None listed
- Dealroom signal
- 68.8/100
- Sub-industry
- AgriTech
- Sector
- Food, Veterinary, Organic, Biotechnology, Crop Protection, Biopesticides, Pesticides, Molecular, Primary Production, Sustainable Development Goals, Regenerative Agriculture
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Nov 2020 | $0 | — | Undisclosed | ↗ |
| LATE VCOther financing | Sep 2019 | $66M | $264M | Cibus Capital · ADM Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for M2i Life Sciences is 520 monthly website visits, down 65.3% over the last three months. M2i Life Sciences's team grew 6.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Eurazeo
Cibus Capital
ADM Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about M2i Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See M2i Life Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.